Showing 2331-2340 of 2494 results for "".
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- Alcon Broadens US Availability of MARLO Digital Platformhttps://modernod.com/news/alcon-broadens-us-availability-of-marlo-digital-platform/2478153/Alcon announced broader US availability of its MARLO digital platform offered within independent OD practice. The platform allows patients to order, reorder and track their Alcon contact lens order online and have their lenses shipped right to their doorstep, while keeping the relationship and re
- Medicare Sticks With E/M Pay Plan Over Some Groups’ Objectionshttps://modernod.com/news/medicare-sticks-with-e-m-pay-plan-over-some-groups-objections/2478136/The Trump administration is sticking with a plan to boost certain Medicare pay for many primary care and other specialties focused heavily on office visits while lowering that for other groups to balance these increased costs, according to a Medscape
- Bausch + Lomb Launches -2.75 Cylinder for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-2-75-cylinder-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2478129/Bausch + Lomb announced the US launch of the -2.75 cylinder parameter offering for Biotrue ONEday for Astigmatism daily disposable contact lenses, the first and only toric daily disposable with a -2.75 cylinder. This new parameter offering will be available for same day fitting in a standard fit
- CMS Proposes Changes to Docs’ Medicare Payments for 2021, Including Payment Cuts for Some Specialtieshttps://modernod.com/news/cms-proposes-changes-to-docs-medicare-payments-for-2021-including-payment-cuts-for-some-specialties/2478125/Federal health officials released a proposed rule that sets 2021 Medicare payment rates for physicians and includes changes to the Merit-based Incentive Payment System, according to a FierceHealthcare
- iOR Partners Welcomes Tom Frinzi to their Boardhttps://modernod.com/news/ior-partners-welcomes-tom-frinzi-to-their-board/2478104/iOR Partners, a provider of office-based surgery in ophthalmology, announced that industry veteran Tom Frinzi has joined their Board of Directors. “We are thrilled that Tom Frinzi is joining our Board. He bring
- AcuFocus Announces Extended Diopter Range for the IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/AcuFocus announced that the IC-8 small aperture IOL power range now extends from +10.0 D to +30.0 D (0.50 D steps), offering eye care physicians the opportunity to provide more patients an uninterrupted extended range
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the
- AffronEYE Saffron Extract Aims to Reduce Risks of Long-Term Blue-Light Induced Eye Injuryhttps://modernod.com/news/affroneye-saffron-extract-aims-to-reduce-risks-of-long-term-blue-light-induced-eye-injury/2478051/In a digital era, the increasing dependence on screens and technology particularly among gamers is prolonging exposure to blue light. Madrid, Spain-based nutraceutical company Pharmactive Biotech Products offers its proprietary affronEYE saffron ingredient, a fast